TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01821937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: faldaprevir(high dose)
Description: faldaprevir(high dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to high dose treatment in random order

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir(low dose)
Description: faldaprevir(low dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to low dose treatment in random order
Study: NCT03411785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPC+ model
Description: CPC+ practices receive a monthly care management fee and prospective performance-based incentive payment on top of traditional payments. Some practices will also receive some payment that shifts away from fee-for-service. In addition, CPC+ practices will receive learning and health IT support and data feedback to implement processes to meet care delivery requirements and achieve five primary care functions.
Study: NCT03554031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Growth Hormone (rhGH) Injection
Description: Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.
Study: NCT02928731

Intervention type: OTHER
Intervention: Questionnaires set 1
Description: Participants were asked to respond to the Chinese version of the Coping Behavior Checklist for Chinese Children, the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth, and the Pediatric Quality of life Inventory: cancer module.

Intervention type: OTHER
Intervention: Questionnaires set 2
Description: Participants were asked to respond to the Chinese version of the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth,and the Pediatric Quality of life Inventory: generic module
Study: NCT02539316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoflipid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Médialipides
Study: NCT00305344

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Umbilical Cord Blood Transfusion
Description: Cord Blood infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cord blood
Description: Develop Cord blood vaccine
Study: NCT00570908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Sutent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: concurrently

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT
Description: Whole Brain Radiotherapy 30 Gy in 10 fractions
Study: NCT01275742

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Brief Cognitive Therapy Intervention
Description: The intervention group will receive an individual, 30 minute, scripted cognitive therapy session. This intervention will be delivered by an Advanced Practice Registered Nurse or a trained research nurse. An iPad will guide the outline of the intervention. The nurse will discuss depression in heart disease and the connection between thoughts, emotions, and behaviors. The nurse will ask the patient to describe a recent stressful experience and discuss thoughts that the patient has been experiencing. Two techniques for challenging negative thinking will be introduced to the patient: thought stopping and affirmations. The nurse will ask the patient to practice these techniques at home. After the patient has practiced both techniques, the nurse will leave the patient with a booklet with the intervention. At 1-2 weeks, the nurse will administer a booster session over the phone. This session will last 10-15 minutes and will reinforce the techniques learned during the brief CT intervention.
Study: NCT03786744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASD CB-MNC injection.
Description: CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard therapy.
Description: The standard therapy can include drugs, special psychology training etc.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard therapy.
Description: The standard therapy can include drugs, special psychology training etc.
Study: NCT03097406

Intervention type: PROCEDURE
Intervention: Global Unite hemiarthroplasty
Description: A hemiarthroplasty used for complex fractures of the proximal humerus.

Intervention type: PROCEDURE
Intervention: Global Advantage
Description: A total shoulder prosthesis used for osteoarthritis

Intervention type: PROCEDURE
Intervention: Global FX
Description: A hemiarthroplasty used for complex fractures of the proximal humerus.

Intervention type: PROCEDURE
Intervention: Global Unite total shoulder arthroplasty
Description: A total shoulder prosthesis used for osteoarthritis
Study: NCT00284193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIIa-FEIBA therapy for hemophilia A inhibitors
Description: DOses tailored per ex vivo spiking thrombin generation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEIBA- Activated Prothrombin Complexes
Study: NCT04657042

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Four-dimensional MRI of torso

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Four-dimensional MRI of torso

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Four-dimensional MRI of torso
Study: NCT02127138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus eluting Drug stent
Description: Use the Sirolimus-eluting Drug stents has been approved by the CFDA，But does not allow use taxol-eluting Drug stents and Drug-eluting stent without Polymer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus eluting Drug stent
Description: Use the Sirolimus-eluting Drug stents has been approved by the CFDA，But does not allow use taxol-eluting Drug stents and Drug-eluting stent without Polymer.
Study: NCT01447576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: Once daily dosing during the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: OPC-34712, Oral Tablets, 0.25 - 3 mg
Study: NCT01902186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir and atazanavir and ritonavir
Description: switch tenofovir/emtricitabine to raltegravir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir/emtricitabine and atazanavir and ritonavir
Description: no change in antiretroviral treatment; patients will continue their regimen (tenofovir/emtricitabine and atazanavir and ritonavir)
Study: NCT03799419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification for interpretation bias
Description: Eight sessions of scenario-based CBM-I training for OCD will be administered, based on the widely-used paradigm of ambiguous scenario training developed by Mathews and Mackintosh (2000), in which participants are presented with scenarios that are ambiguous in whether or not they are threatening. Participants will complete a computer task consisting of a series of written scenarios designed to improve interpretation and attributional biases; these scenarios conclude with word fragments, which participants must fill in to resolve the ambiguity.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Psychoeducation
Description: Eight sessions of psychoeducation will be administered, which will describe symptoms of anxiety, the nature of biased thinking in anxiety, and summarize common psychosocial as well as pharmacological treatments for anxiety. The sessions will provide relevant information but will not provide training in changing thinking styles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach avoidance training
Description: Eight sessions of this computerized training program will be used to train approach tendencies, following previously validated procedures (Najmi, Kuckertz, \& Amir, 2010). During the training program, participants will view a series of these images and be prompted to push or pull a joystick according to prompts on the screen, instead of the content of the picture. Avoidance will be stimulated through both pushing away (images on the screen will decrease in size upon the joystick being pushed), and approach will be stimulated through pulling towards pictures (images will increase in size to simulate approach).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Inactive sham approach avoidance training
Description: Eight sessions of the approach avoidance training will be administered, however the percentage of push vs pull trials will be altered in this sham version of the training.
Study: NCT01515852

Intervention type: PROCEDURE
Group type: OTHER
Intervention: general anesthesia in stereotactic biopsy
Description: stereotactic biopsy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: local anesthesia in stereotactic biopsy
Description: stereotactic biopsy
Study: NCT01103921

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose
Description: 25% dose at 2-week intervention assigned to subjects.

Intervention type: OTHER
Group type: OTHER
Intervention: Fructose
Description: 25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.

Intervention type: OTHER
Group type: OTHER
Intervention: High-Fructose Corn Syrup
Description: 25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.

Intervention type: OTHER
Group type: OTHER
Intervention: No sugar (Aspartame)
Description: 0% dose at 2-week intervention assigned to subjects.
Study: NCT01786304

Intervention type: PROCEDURE
Intervention: Sacral nerve stimulation
Description: implantation of a stimulation electrode in one of the S2-S3-S4 sacral hole then connected to a subcutaneous stimulator for permanent stimulation of the sacral nerve
Study: NCT03278743

Intervention type: OTHER
Intervention: Cognitive performance and cognitive decline
Description: Assess the global and domain specific (memory, speed and attention) cognitive function at baseline and over 5 years in the high vs. low/moderate tea consumption groups

Intervention type: OTHER
Intervention: Cognitive performance and cognitive decline
Description: Assess the global and domain specific (memory, speed and attention) cognitive function at baseline and over 5 years in the high vs. low/moderate tea consumption groups
Study: NCT02476942

Intervention type: DRUG
Intervention: Bypassing Agents
Description: Episodic or prophylactic treatment with the use of bypassing agents must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.

Intervention type: DRUG
Intervention: FVIII Replacement
Description: Episodic or prophylactic treatment with the use of FVIII replacement must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
Study: NCT01179503

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium
Description: 600 mg calcium carbonate twice daily (total of 1200 mg/day) for 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D plus calcium
Description: 1000 IU of vitamin D3 twice daily (for a total of 2000 IU/day) plus 600 mg calcium carbonate twice daily (for a total of 1200 mg/day)
Study: NCT01301599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination therapy
Description: alpha blocker and 5-alpha-reductase inhibitor medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha blocker monotherapy
Description: alpha blocker monotherapy group
Study: NCT02774187

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox Protocol
Description: Oxaliplatin , fluorouracil, and leucovorin
Study: NCT02373137

Intervention type: PROCEDURE
Group type: OTHER
Intervention: DSAEK

Intervention type: PROCEDURE
Group type: OTHER
Intervention: DMEK
Study: NCT01301599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 alpha reductase inhibitor monotherapy
Description: 5 alpha reductase inhibitor monotherapy
Study: NCT01267669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: Emergency EVL plus Somatostatin (250 mcg/hr) infusion for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Emergency EVL plus placebo infusion for 5 days
Study: NCT00932971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-IFN alfa-2a, Tenofovir
Description: Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PEG-IFN alfa-2a, placebo
Description: Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Placebo, once daily, orally
Study: NCT02373137

Intervention type: DEVICE
Group type: OTHER
Intervention: Endoserter
Description: The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Study: NCT04962451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor + ASA
Description: On day 1, ticagrelor loading dose (2 tablets, ticagrelor 90mg) was given, followed by ticagrelor 90mg, twice daily Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+ASA
Description: Placebo loading dose on day 1 (2 tablets, matched with ticagrelor 90mg), followed by placebo twice daily (matched with ticagrelor 90mg) Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
Study: NCT02546947

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Train of four monitoring
Description: with an end point of one or two response at orbicularis oculi to TOF stimulation
Study: NCT02447653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G7 HA Acetabular Component
Description: G7 HA Acetabular Component

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: G7 PPS Acetabular Component
Description: G7 PPS Acetabular Component
Study: NCT03777852

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: First Questionnaire application
Description: Women with breast cancer will respond to the First Breast Q questionnaire before treatment with breast cancer reconstruction surgery.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Second Questionnaire application
Description: Women with breast cancer will respond to the Second Breast Q questionnaire after treatment with breast cancer reconstruction surgery.
Study: NCT02373137

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.

Intervention type: DRUG
Group type: OTHER
Intervention: Ofloxacin
Description: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.

Intervention type: DRUG
Group type: OTHER
Intervention: Ofloxacin
Description: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.

Intervention type: DRUG
Group type: OTHER
Intervention: Tropicamide
Description: Tropicamide is a prescription drug used to dilate pupils during an eye exam.

Intervention type: DRUG
Group type: OTHER
Intervention: Tropicamide
Description: Tropicamide is a prescription drug used to dilate pupils during an eye exam.

Intervention type: DRUG
Group type: OTHER
Intervention: Phenylephrine
Description: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.

Intervention type: DRUG
Group type: OTHER
Intervention: Phenylephrine
Description: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.

Intervention type: DEVICE
Group type: OTHER
Intervention: Jones Tube
Description: The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.
Study: NCT01720485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine + Prednisolone
Description: 1 tablet 3 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexchlorpheniramine + Betamethasone
Description: 1 tablet 3 times a day
Study: NCT04144868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric Oxygen
Study: NCT01961167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stenting of common and/or external iliacs
Description: Balloon expandable stenting of iliac occlusive disease
Study: NCT04089878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration
Description: Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Antibiotics, nutrition and supportive treatment
Study: NCT04013880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDA Inhibitor E7727/Decitabine Combination Agent ASTX727
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDH-1 Inhibitor FT-2102
Description: Given by mouth
Study: NCT00154375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: Imatinib was supplied as 100 mg and 400 mg tablets packaged in polyethylene bottles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Study: NCT01209247

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nasal, rectal and pharyngeal swabs
Description: Nasal, rectal and pharyngeal swabs were performed before, during, and one month after the end of FQ treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal, rectal and pharyngeal swabs
Description: Nasal, rectal and pharyngeal swabs were performed before, during, and one month after the end of FQ treatment.
Study: NCT00048997

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: PCI is given to the whole brain in a dose of 2 Gy per fraction, 5 days per week, for 3 weeks for a total dose of 30 Gy.

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Study: NCT04592679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES-C
Description: The participants were submitted to 20 sessions of FES-C three/five times per week. Each session lasted about 30'.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: The participants were submitted to 20 sessions of standard rehabilitation for lower limbs with manual mobilization, three/five times per week. Each session lasted about 30'.
Study: NCT03307460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-AE105
Description: PET/MRI scan
Study: NCT01289301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mTOR inhibitor (everolimus)
Description: calcineurin-inhibitor based immunosuppression will be switched to immunosuppression based on m-TOR inhibitor (everolimus trough level 3-7ng/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine or tacrolimus
Description: calcineurin inhibitor (cyclosporine or tacrolimus) will be continued (trough level 60-90ng/mL resp 3-7ng/mL)
Study: NCT05687409

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir 0.5 mg
Description: Orally administered Entecavir 0.5 mg, once a day. For six months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg
Description: Orally administered Entecavir 0.5 mg, once a day. For six months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A 10-g packet of lactulose oral solution and three capsules of probiotics
Description: A 10-g packet of lactulose oral solution and three capsules of probiotics (each containing \> 4.2×106 CFU Clostridium butyricum and \> 4.2×105 CFU Bifidobacterium longum infantis).~Participants orally administered the contents three times daily after meals. For six months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: A 10-g packet of glucose oral solution and three capsules of starch
Description: A 10-g packet of glucose oral solution and three capsules of starch. Participants orally administered the contents three times daily after meals. For six months.
Study: NCT01043484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab + Capecitabine + Radiotherapy
Description: Bevacizumab (5 mg/kg; days 1, 15 and 29) Capecitabine (825 mg/m2/12h, 5 days/w) Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine + Radiotherapy
Description: Capecitabine (825 mg/m2/12h, 5 days/w) and Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
Study: NCT01129271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT01712269

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Weight-loss (bariatric) surgery
Description: Subjects will undergo bariatric surgery which will assist weight loss
Study: NCT03358238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly review
Description: Each week in the study, an interviewer will review manic and depressive symptoms self-reported by a participant and patterns of activity, sleep, and heart rate collected by the participant's activity tracker.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No weekly review
Description: An interviewer will not review self-report symptoms and patterns collected from an activity tracker.
Study: NCT02579395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative implementation Intentions
Description: With spouse/romantic partner